A Phase 3 interventional study of Dexamethasone and Punctum Plug in Post Ocular Surgical Inflammation and Pain, sponsored by Ocular Therapeutix, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-31.
Sponsored by Ocular Therapeutix, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing dexamethasone in Pain — 9 open to participants now, 10 under way, 2 of them phase 3. Dexamethasone · Pain.
Among the 64 studies testing dexamethasone in Pain, this one is the 3rd largest by enrollment, is one of 8 that started in 2014, is one of 9 in phase 3, and was the 21st registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →9 of the 64 studies testing dexamethasone in Pain are open now, in 7 countries. Recruiting first, the newest first:
Elsan · Sites in France
Ages 18+
Nishtar Medical University · Sites in Pakistan
Ages 18–40
Balgrist University Hospital · Sites in Switzerland
Ages 18–99 · Healthy volunteers
Dow University of Health Sciences · Sites in Pakistan
Ages 18–50 · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 18+
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 9 · Phase 4 29
First in 2005; this study’s year is marked. 8 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 247 is above the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 89 across the 64 interventional studies. Of the 42 that completed or were terminated, 16 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 64 have an industry lead sponsor. The 10 most frequent:
Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Ocular Therapeutix, Inc. has 4 studies filed under Pain — fewer than ten, so there is no comparison to draw.
2 of the studies testing dexamethasone in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07208799Nishtar Medical UniversityComparison of Submucosal Dexamethasone and Methylprednisolone in Postoperative Sequelae of Parasymphsis Fractures | 2026-11-30 |
| NCT07097493Wake Forest University Health SciencesLiposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 64 studies testing dexamethasone in Pain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Resorbable hydrogel drug delivery vehicle containing dexamethasone
Drug: Dexamethasone · Drug: Punctum Plug
Resorbable hydrogel drug delivery vehicle containing no drug
Drug: Punctum Plug
Absence of Cells in Anterior Chamber of the Study Eye
Time frame: Day 14
Absence of Pain in Study Eye
Time frame: Day 8
| Milestone | OTX-DP (Dexamethasone Punctum Plug) | PVPP (Placebo Punctum Plug) |
|---|---|---|
| Started | 164 | 83 |
| Completed | 163 | 81 |
| Not completed | 1 | 2 |
| Participants | OTX-DP (Dexamethasone Punctum Plug) | PVPP (Placebo Punctum Plug) |
|---|---|---|
| Absence of Cells in Anterior Chamber of the Study Eye | 54 | 12 |
| Participants | OTX-DP (Dexamethasone Punctum Plug) | PVPP (Placebo Punctum Plug) |
|---|---|---|
| Absence of Pain in Study Eye | 131 | 36 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OTX-DP (Dexamethasone Punctum Plug) | — | 0/162 (0%) | 37/162 (22.8%) |
| PVPP (Placebo Punctum Plug) | — | 1/84 (1.2%) | 31/84 (36.9%) |
| Event | OTX-DP (Dexamethasone Punctum Plug) | PVPP (Placebo Punctum Plug) |
|---|---|---|
| hypopyonEye disorders | 0/162 | 1/84 |
| Event | OTX-DP (Dexamethasone Punctum Plug) | PVPP (Placebo Punctum Plug) |
|---|---|---|
| inflammationEye disorders | 37/162 | 31/84 |
| Age, Categorical(Participants) | OTX-DP (Dexamethasone Punctum Plug) | PVPP (Placebo Punctum Plug) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 56 | 16 | 72 |
| >=65 years | 108 | 67 | 175 |
| Sex: Female, Male(Participants) | OTX-DP (Dexamethasone Punctum Plug) | PVPP (Placebo Punctum Plug) | Total |
|---|---|---|---|
| Female | 103 | 44 | 147 |
| Male | 61 | 39 | 100 |
The record gives a start of Feb 2014, a primary completion of Dec 2014 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2020, 5 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone